DYRK2-IN-1

• UNSPSC Description:

  DYRK2-IN-1 (Compd 54) is an orally bioavailable DYRK2 inhibitor, with an IC50 of 14 nM. DYRK2-IN-1 (Compd 54) can be used in the study of prostate cancer[1].

• Target Antigen:

  DYRK

• Type:

  Reference compound

• Related Pathways:

  Protein Tyrosine Kinase/RTK

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/dyrk2-in-1.html

• Solubility:

  10 mM in DMSO

• Smiles:

  FC1=CN=C(N=C1C2=CC=C3N=C(SC3=C2)N(CC)CC)NC4=NC=C(C=C4)C(N5CCN(CC5)C(C6CC6)=O)=O

• Molecular Weight:

  574.67

• References & Citations:

  [1]Kai Yuan, et al. Discovery of Potent, Selective, and Orally Bioavailable DYRK2 Inhibitors for the Treatment of Prostate Cancer. J Med Chem. 2023 Dec 14;66(23):16235-16256.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported